Abstract

B Crestani reports personal fees and non-financial support from astra-zeneca, grants, personal fees and non-financial support from boehringer ingelheim, non-financial support from cardif, non-financial support from lvl, personal fees and non-financial support from apelis, grants from medImmune, personal fees and non-financial support from sanofi, outside the submitted work.

M Kolb reports grants and personal fees from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Gilead, grants from Actelion, grants from Respivert, personal fees from Astra Zeneca, personal fees from Prometic, personal fees from Genoa, grants from Canadian Institute for Health Research, grants from Canadian Pulmonary Fibrosis Foundation, outside the submitted work.

B Wallaert: No conflict of interest

M Quaresma and W Stansen are employees of Boehringer Ingelheim.

L Richeldi reports grants and personal fees from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from InterMune, personal fees from Medimmune, personal fees from Biogen-Idec, personal fees from Sanofi-Aventis, personal fees from Roche, personal fees from Takeda, personal fees from ImmuneWorks, personal fees from Shionogi, outside the submitted work.